tiprankstipranks
Trending News
More News >
StemCell Institute (JP:7096)
:7096
Japanese Market
Advertisement

StemCell Institute (7096) AI Stock Analysis

Compare
0 Followers

Top Page

JP:7096

StemCell Institute

(7096)

Rating:67Neutral
Price Target:
¥1,107.00
▲(8.53%Upside)
StemCell Institute's financial performance is strong, particularly in revenue growth and profitability. However, technical indicators suggest a lack of momentum, and valuation metrics indicate the stock may be overvalued. Negative free cash flow also poses a potential risk.

StemCell Institute (7096) vs. iShares MSCI Japan ETF (EWJ)

StemCell Institute Business Overview & Revenue Model

Company DescriptionStemCell Institute (7096) is a biotechnology company specializing in the research and development of stem cell therapies. The company operates within the healthcare sector, focusing on regenerative medicine and cellular treatments to address a variety of medical conditions. Its core services include conducting clinical trials, developing innovative stem cell-based products, and providing stem cell banking services.
How the Company Makes MoneyStemCell Institute generates revenue primarily through the development and commercialization of stem cell therapies. The company earns money by partnering with healthcare providers and pharmaceutical companies to co-develop and distribute its products. Additional revenue streams include fees from clinical trials conducted for new treatments, as well as payments for stem cell banking services offered to individuals and medical institutions. Significant partnerships with research organizations and hospitals further enhance its earnings potential by expanding its reach and facilitating new product development.

StemCell Institute Financial Statement Overview

Summary
StemCell Institute exhibits strong revenue growth and profitability, supported by robust margins and a solid capital structure. While the balance sheet reflects financial stability, the negative free cash flow warrants attention. Overall, the company is well-positioned in the biotechnology sector, but improvements in cash flow management could enhance financial health.
Income Statement
85
Very Positive
StemCell Institute shows strong revenue growth with a 7.97% increase from the previous year. The gross profit margin is robust at 63.16%, and the net profit margin has improved to 14.40%, indicating efficient cost management and profitability. The EBIT and EBITDA margins of 15.62% and 25.94% respectively, reflect solid operational efficiency.
Balance Sheet
78
Positive
The company maintains a healthy balance sheet with a low debt-to-equity ratio of 0.20, showcasing financial stability. The equity ratio of 35.02% suggests a strong capital structure. However, the return on equity is moderate at 14.68%, indicating potential for improved profitability.
Cash Flow
72
Positive
Operating cash flow to net income ratio is strong at 1.21, indicating good cash generation relative to net income. However, the free cash flow has turned negative, indicating potential challenges in cash management. The decrease in free cash flow from the previous year is a concern, suggesting a need for better capital expenditure management.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue2.68B2.48B2.09B1.78B1.41B
Gross Profit1.69B1.58B1.34B1.11B924.21M
EBITDA695.19M534.00M383.89M309.47M119.66M
Net Income385.80M310.98M198.03M133.73M62.37M
Balance Sheet
Total Assets7.50B6.54B5.81B5.22B3.96B
Cash, Cash Equivalents and Short-Term Investments3.20B2.85B3.32B3.51B2.74B
Total Debt518.96M8.78M5.89M0.000.00
Total Liabilities4.87B3.85B3.51B3.11B2.64B
Stockholders Equity2.63B2.69B2.30B2.10B1.32B
Cash Flow
Free Cash Flow-10.11M132.97M39.77M264.81M-164.34M
Operating Cash Flow467.69M334.63M99.67M469.29M239.00M
Investing Cash Flow-259.08M-811.77M-285.10M404.17M-520.26M
Financing Cash Flow146.70M-1.33M-869.00K644.37M0.00

StemCell Institute Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1020.00
Price Trends
50DMA
1051.64
Negative
100DMA
1178.80
Negative
200DMA
1346.38
Negative
Market Momentum
MACD
-5.18
Negative
RSI
50.20
Neutral
STOCH
30.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Negative. The current price of 1020 is above the 20-day moving average (MA) of 988.70, below the 50-day MA of 1051.64, and below the 200-day MA of 1346.38, indicating a neutral trend. The MACD of -5.18 indicates Negative momentum. The RSI at 50.20 is Neutral, neither overbought nor oversold. The STOCH value of 30.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7096.

StemCell Institute Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
¥13.87B284.55
0.72%-13.57%-106.11%
67
Neutral
¥10.53B27.29
7.98%24.12%
58
Neutral
¥25.02B
-2.34%-278.32%
52
Neutral
$7.59B0.18-63.14%2.16%16.34%0.64%
49
Neutral
¥21.32B215.00
8.46%49.97%
47
Neutral
¥19.20B
-100.00%-1079.89%
46
Neutral
¥16.40B
-4.04%-0.88%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7096
StemCell Institute
1,020.00
-634.61
-38.35%
JP:4599
StemRIM Inc.
309.00
-145.00
-31.94%
JP:4880
CellSource Co., Ltd.
694.00
-859.43
-55.32%
JP:4978
ReproCELL Inc.
225.00
85.00
60.71%
JP:7774
Japan Tissue Engineering Co., Ltd.
629.00
-45.00
-6.68%
JP:7776
CellSeed Inc.
478.00
-37.00
-7.18%

StemCell Institute Corporate Events

StemCell Institute Expands into Southeast Asia with Joint Venture
Jul 15, 2025

StemCell Institute Inc. has entered a joint venture with BIG RAINBOW INVESTMENT PTE. LTD., the family office of Sinar Mas Group, to expand its cell banking business in Southeast Asia. This strategic partnership aims to leverage StemCell’s expertise and the local networks of Sinar Mas Group to strengthen its presence and achieve sustainable growth in the region, with plans to explore related regenerative medicine services.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 26, 2025